# RLX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/RLX) · [Earnings tab](https://www.lopjlb.com/stock/RLX?tab=earnings) Updated: 2026-08-14T07:25:28 Quarters analyzed: 8 ## Cross-quarter narrative Across the earnings calls, RLX demonstrated strong revenue growth driven by international expansion, with a significant increase in international mix to 76.5% by FY2025. The company navigated regulatory challenges, adapting to bans on disposable products in various regions and investing in compliant products. Gross margins expanded, aided by favorable revenue mix and cost discipline. RLX also focused on returning cash to shareholders through dividends and share repurchases, with cumulative returns exceeding $500M since IPO. The company's globalization strategy and product innovation, including the rollout of modern oral products and heated tobacco, are key areas of focus. ## Latest CallCard · Q1 RLX Q1 2026: Revenue +96% YoY to RMB1.59B, driven by international expansion (>70% of revenue), Nexus manufacturing operational, UK regulatory tailwind, margins expanding, strong cash position with dividends paid. **Guidance:** vague — No explicit forward guidance provided; management noted unannounced M&A projects not included in guidance and focus on markets with clear operational levers. **Tone:** mgmt 0.8 · Q&A pressure 0.2 · divergence 0.6 Prepared remarks emphasize robust start, strong growth, structural regulatory tailwinds, operational integration success, and quality-led strategy. ### Demand visibility Strong international demand with regulatory tailwinds; China stable; some front-loading distortion from export tax change. International business >70% of revenue for several quarters, driven by Europe and Asia. UK generational smoking ban positions e-vapor as primary harm reduction channel. Asia #1 brand enables efficient entry into neighboring markets. China export tax rebate cancellation caused temporary channel front-loading in Q1, now largely behind. ### Margins / costs Gross margin expanded to 31.8% (+320bps YoY); non-GAAP operating margin 19.6% (+630bps YoY) on favorable mix and supply chain optimization. Gross margin improvement driven by favorable product mix and ongoing supply chain optimization. Operating leverage from revenue growth translated to 187.9% YoY increase in non-GAAP operating income. Working capital efficient: receivables 15 days, inventory 32 days, payables 49 days. ### Capital allocation Cash position RMB14.53B (~USD2.1B) after dividend payments; investing in European warehouse, Nexus manufacturing, and evaluating M&A; returning capital via dividends. Total financial assets decreased from RMB15.73B to RMB14.53B sequentially due to dividend payments. Invested in new local warehouse facility for European acquired entity. Nexus integrated smart manufacturing facility fully operational. Actively evaluating European M&A with disciplined valuations. No share buyback mentioned. ### Milestones - **Nexus integrated smart manufacturing facility** [delivered]: Fully operational, integrating R&D, manufacturing, commercial operations. - **European acquired company integration** [on_track]: Strategic alignment, capital support, new warehouse facility invested. - **UK market expansion** [on_track]: Leveraging generational smoking ban, HMRC licensing, vaping product duty. - **Modern oral products scaling** [on_track]: Steadily scaling production capacity, identifying new distribution channels. - **HMB heated tobacco launch** [delayed]: Technical capabilities exist but timing not optimal; no immediate launch plan. - **Entry into 2 new markets (Southeast Asia and Europe)** [delivered]: Successfully entered in Q1 2026. - **European M&A evaluation** [new]: Actively evaluating opportunities with ## Quarter one-liners - **2026 Q1:** RLX Q1 2026: Revenue +96% YoY to RMB1.59B, driven by international expansion (>70% of revenue), Nexus manufacturing operational, UK regulatory tailwind, margins expanding, strong cash position with dividends paid. - **2025 Q4:** RLX posted 44% FY2025 revenue growth, 76.5% international mix, margins 31.4% in Q4, $2.2B cash, $500M returns; advancing global expansion in Europe/Asia and nicotine pouch rollout. - **2025 Q3:** RLX delivered Q3 2025 net revenue of RMB 1.129B (+49% YoY) and non-GAAP operating profit of RMB 188M, driven by international expansion (70-80% of revenue), APAC franchise model, and UK adaptation to disposable ban; Mainland China recovery modest at 13% of 2021 level amid unregulated market. - **2025 Q2:** RLX Q2 2025: 40% YoY revenue growth to RMB 880M, non-GAAP op profit RMB 116M; multi-category expansion, European acquisition, regulatory tailwinds, dividend $0.01/share. - **2025 Q1:** RLX posted 47% YoY revenue growth and higher margins while navigating tighter global regulations and a shift to larger‑capacity “Big Puff” products, remaining upbeat on international expansion but cautious on timing. - **2024 Q4:** RLX posts 73% YoY revenue growth in 2024 driven by international expansion; Q4 non-GAAP operating profit rises for 5th straight quarter; plans H2 2025 expansion to new markets amid regulatory shifts. - **2024 Q3:** RLX posted strong Q3 revenue growth and margin expansion, highlighted new compliant disposable and premium products, secured IP certification, and outlined international expansion while noting regulatory and illegal‑product challenges. - **2024 Q2:** RLX reported 66% YoY revenue growth, highlighted new high‑value pod launches and lab certification, but flagged regulatory bans and local market adaptation as key overseas challenges. ## Theme arcs - **International Expansion** (improving): Driven by APAC franchise model and European acquisition - **Regulatory Adaptation** (stable): Company adapting to bans and regulatory changes - **Margin Expansion** (improving): Favorable revenue mix and cost discipline - **Product Innovation** (improving): Rollout of modern oral products and heated tobacco - **Shareholder Returns** (improving): Cumulative returns exceeding $500M since IPO ## Fear persistence - **Regulatory Risk** [recurring]: Ongoing concerns about bans and regulatory changes - **Market Shift Risk** [recurring]: Transition from disposable to Big Puff devices may suppress per-ml pricing - **Competitive Pressure** [recurring]: Larger tobacco players and agile disposable brands could erode market share - **Geographic Concentration** [recurring]: Heavy reliance on international markets makes RLX vulnerable to regional regulatory changes - **Cash Conversion Cycle** [resolved]: No longer mentioned as a concern ## Guidance path 2024 Q2:maintained → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/RLX`